Open an account

Lisata Therapeutics

LSTA · NASDAQ

$1.04+$0.04 (+4.00%)TodayMarket closed ·
Prev close $1.00

LSTA analyst rating

HoldConsensus of 2 analysts over the last 12 months. 0% rate it a buy.
  • Strong buy0
  • Buy0
  • Hold2
  • Underperform0
  • Sell0

12-month price target · 3 analysts

Average $15.30 (+1371.2% upside)

Low
$15.15
Now
$1.04
High
$15.75

Upgrades and downgrades

The latest rating actions, newest first

LSTA analyst upgrades, downgrades and rating actions
FirmDateActionRating
HC Wainwright & Co.May 15, 2026DowngradeBuy → Neutral
Brookline CapitalJan 21, 2026DowngradeBuy → Hold

The case for and against

Updated Feb 9, 2026

Bull case

Lisata Therapeutics Inc. has demonstrated notable progress with its lead candidate, certepetide, as evidenced by positive preliminary data from Cohort A presented at ASCO GI. The results indicate a favorable trend in overall survival, highlighting four complete responses within the certepetide treatment group, which underscores the potential efficacy of the drug. Additionally, Cohort B data suggests that administering a second dose of certepetide may further enhance progression-free survival (PFS) and overall response rate (ORR) for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), reflecting the strong therapeutic promise of the investigational treatment.

Bear case

Lisata Therapeutics Inc faces significant risks that contribute to a negative outlook on its stock, primarily due to the potential for failed or inconclusive clinical trials that could derail the progress of its investigational drug, certepetide. Additionally, the company's reliance on securing adequate funding to advance its drug development is a concern; any shortfall in funding could hinder its operational capabilities. The overall financial health of the company is further jeopardized by these uncertainties, thereby casting doubt on its ability to achieve favorable valuation outcomes.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.